We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDX icon
26
Becton Dickinson
BDX
$43B
$112M 1.14%
466,961
-5,528
-1% -$1.36M
SYK icon
27
Stryker
SYK
$123B
$111M 1.13%
422,332
+77,818
+23% +$20.8M
CRSP icon
28
CRISPR Therapeutics
CRSP
$4.71B
$109M 1.11%
974,684
+7,800
+0.8% +$980K
PODD icon
29
Insulet
PODD
$11.5B
$109M 1.1%
382,994
+60,875
+19% +$17.4M
AXNX
30
DELISTED
Axonics, Inc. Common Stock
AXNX
$105M 1.06%
1,608,794
-121,677
-7% -$8.3M
ALGN icon
31
Align Technology
ALGN
$12.6B
$104M 1.06%
157,031
+261
+0.2% +$177K
JAZZ icon
32
Jazz Pharmaceuticals
JAZZ
$15.4B
$100M 1.02%
769,238
+224,488
+41% +$33.9M
EW icon
33
Edwards Lifesciences
EW
$49.3B
$98.5M 1%
869,951
-20,305
-2% -$2.32M
INSP icon
34
Inspire Medical Systems
INSP
$1.49B
$98.1M 1%
421,058
+47,832
+13% +$9.98M
RDUS
35
DELISTED
Radius Health, Inc.
RDUS
$96.4M 0.98%
7,768,714
+237,300
+3% +$3.42M
SWAV
36
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$95.6M 0.97%
464,247
-52,668
-10% -$10.3M
RVMD icon
37
Revolution Medicines
RVMD
$39.2B
$95.2M 0.97%
3,458,805
+1,604,000
+86% +$46.7M
EVH icon
38
Evolent Health
EVH
$646M
$94M 0.95%
3,032,678
-605,733
-17% -$14.5M
INSM icon
39
Insmed
INSM
$23.6B
$93.2M 0.95%
3,385,645
+264,744
+8% +$6.95M
HCA icon
40
HCA Healthcare
HCA
$82.2B
$82.9M 0.84%
341,473
+7,200
+2% +$1.76M
NKTR icon
41
Nektar Therapeutics
NKTR
$2.22B
$82.5M 0.84%
306,310
+32,883
+12% +$7.91M
ACCD
42
DELISTED
Accolade Inc
ACCD
$78.4M 0.8%
1,860,203
+135,504
+8% +$6.37M
BMY icon
43
Bristol-Myers Squibb
BMY
$124B
$77.1M 0.78%
1,302,934
-160,498
-11% -$10.6M
SRRK icon
44
Scholar Rock
SRRK
$6.27B
$75.8M 0.77%
2,294,425
-3,200
-0.1% -$112K
BAX icon
45
Baxter International
BAX
$11.5B
$74.3M 0.75%
923,223
+22,600
+3% +$1.79M
IDXX icon
46
Idexx Laboratories
IDXX
$44.8B
$73.5M 0.75%
118,120
– –
MTEM
47
DELISTED
Molecular Templates, Inc.
MTEM
$73M 0.74%
725,200
+83,292
+13% +$8.59M
CNC icon
48
Centene
CNC
$32.8B
$71.9M 0.73%
1,154,545
-231,752
-17% -$15.5M
REGN icon
49
Regeneron Pharmaceuticals
REGN
$71.3B
$64.4M 0.65%
106,410
+750
+0.7% +$466K
HOLX
50
DELISTED
Hologic
HOLX
$64.3M 0.65%
870,662
-43,090
-5% -$3.23M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.